Biogen Inc. (NASDAQ:BIIB) Shares Sold by Wynn Capital LLC

Wynn Capital LLC lessened its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 16.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,316 shares of the biotechnology company’s stock after selling 260 shares during the quarter. Wynn Capital LLC’s holdings in Biogen were worth $201,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Grandfield & Dodd LLC boosted its stake in shares of Biogen by 5.2% during the 3rd quarter. Grandfield & Dodd LLC now owns 1,261 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 62 shares during the last quarter. Quintet Private Bank Europe S.A. raised its holdings in Biogen by 9.7% in the third quarter. Quintet Private Bank Europe S.A. now owns 710 shares of the biotechnology company’s stock valued at $138,000 after acquiring an additional 63 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in Biogen by 25.0% during the 3rd quarter. TD Private Client Wealth LLC now owns 385 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 77 shares during the last quarter. Huntington National Bank grew its holdings in Biogen by 3.5% during the 3rd quarter. Huntington National Bank now owns 2,308 shares of the biotechnology company’s stock worth $447,000 after acquiring an additional 79 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Biogen by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,018 shares of the biotechnology company’s stock worth $767,000 after purchasing an additional 79 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on BIIB. StockNews.com downgraded Biogen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 28th. JPMorgan Chase & Co. lowered their price target on Biogen from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Monday, November 4th. Wolfe Research initiated coverage on Biogen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. UBS Group decreased their price objective on shares of Biogen from $234.00 to $202.00 and set a “neutral” rating for the company in a report on Thursday, October 3rd. Finally, Morgan Stanley cut shares of Biogen from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $285.00 to $204.00 in a report on Thursday, October 31st. Sixteen analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Biogen presently has a consensus rating of “Hold” and an average target price of $230.00.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $143.06 on Wednesday. Biogen Inc. has a 1 year low of $142.42 and a 1 year high of $252.17. The firm has a market cap of $20.85 billion, a P/E ratio of 12.92, a PEG ratio of 1.74 and a beta of -0.07. The stock has a fifty day moving average price of $156.24 and a two-hundred day moving average price of $186.11. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.31. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.43 billion. During the same quarter last year, the business posted $4.36 earnings per share. The company’s quarterly revenue was down 2.5% on a year-over-year basis. Research analysts forecast that Biogen Inc. will post 16.43 EPS for the current fiscal year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.